Brief: Transgene: First Patient Dosed With Oncolytic Virus TG6002

Transgene SA

20/02/2020 18:18

Feb 20 (Reuters) - TRANSGENE SA  TRNG.PA :
    * FIRST PATIENT DOSED WITH TRANSGENE’S ONCOLYTIC VIRUS
TG6002,
ADMINISTERED BY INTRAHEPATIC ARTERY INFUSION IN COLORECTAL
CANCER WITH LIVER METASTASES
    * PHASE 1/2A TRIAL EVALUATES NOVEL ROUTE OF ADMINISTRATION
FOR
TG6002, AN ONCOLYTIC VIRUS THAT ALLOWS PRODUCTION OF
CHEMOTHERAPY AGENT DIRECTLY IN TUMOR
    * FIRST CLINICAL DATA FROM THIS TRIAL TO BE REPORTED DURING
Q2
2020

Source text for Eikon:  ID:nBw1Sgy01a 
Further company coverage:  TRNG.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48587785110;))